- Home
- ICCM vs KRON Comparison
ICCM vs KRON Comparison
Compare ICCM & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- KRON
- Stock Information
- Founded
- ICCM 2006
- KRON 2017
- Country
- ICCM Israel
- KRON United States
- Employees
- ICCM N/A
- KRON N/A
- Industry
- ICCM
- KRON Medicinal Chemicals and Botanical Products
- Sector
- ICCM
- KRON Health Care
- Exchange
- ICCM Nasdaq
- KRON Nasdaq
- Market Cap
- ICCM 72.4M
- KRON 59.8M
- IPO Year
- ICCM N/A
- KRON 2020
- Fundamental
- Price
- ICCM $1.21
- KRON $0.98
- Analyst Decision
- ICCM Strong Buy
- KRON Buy
- Analyst Count
- ICCM 2
- KRON 3
- Target Price
- ICCM $2.70
- KRON $1.63
- AVG Volume (30 Days)
- ICCM 441.2K
- KRON 292.4K
- Earning Date
- ICCM 11-26-2024
- KRON 11-13-2024
- Dividend Yield
- ICCM N/A
- KRON N/A
- EPS Growth
- ICCM N/A
- KRON N/A
- EPS
- ICCM N/A
- KRON N/A
- Revenue
- ICCM $3,671,000.00
- KRON $9,864,000.00
- Revenue This Year
- ICCM $10.03
- KRON $62.21
- Revenue Next Year
- ICCM $62.68
- KRON N/A
- P/E Ratio
- ICCM N/A
- KRON N/A
- Revenue Growth
- ICCM 26.02
- KRON 146.48
- 52 Week Low
- ICCM $0.48
- KRON $0.69
- 52 Week High
- ICCM $1.57
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- ICCM 60.15
- KRON 48.56
- Support Level
- ICCM $1.16
- KRON $0.95
- Resistance Level
- ICCM $1.27
- KRON $1.03
- Average True Range (ATR)
- ICCM 0.10
- KRON 0.05
- MACD
- ICCM -0.02
- KRON -0.00
- Stochastic Oscillator
- ICCM 41.64
- KRON 48.09
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.